Infectious Diseases Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Afric

Infectious Diseases Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)


The global Infectious Diseases Diagnostics Market is experiencing remarkable growth, with revenues reaching US$ 37 billion in 2024. Projections indicate that the market is on a trajectory to achieve a valuation of US$ 54 billion by the end of 2031, driven by several key factors shaping the industry.

Rising Incidence of Infectious Diseases and Focus on Evidence-based Medicine:

The prevalence of infectious diseases, including respiratory ailments and sexually transmitted infections, is surging worldwide. This has led to an imperative need for the diagnosis of these infectious diseases, driving growth in the infectious diseases diagnostics market.

Evidence-based medicine (EBM) is playing a pivotal role in healthcare, enhancing the quality of care, patient satisfaction, and cost-efficiency. EBM emphasizes evidence-driven diagnosis, resulting in a surge in demand for diagnostic kits. Rapid test kits are becoming increasingly essential as the global population grapples with infectious diseases, further boosting market growth.

Reliable Test Kits with Low-Cost Solutions:

Efficient diagnostic test kits for infectious diseases are currently in limited supply. The high cost of existing test kits and a lack of accessible diagnostic tools have prompted companies to focus on creating affordable and reliable solutions. Extensive research and development efforts are underway to produce highly accurate and sensitive diagnostic kits, creating new opportunities for market players.

Government Initiatives Driving Growth:

Various countries are proactively investing in infectious disease prevention to reduce healthcare costs. For instance, the India Health Fund, in collaboration with the Office of the Principal Scientific Adviser to the Government of India, is soliciting innovations to address urgent issues related to the control, treatment, and cure of infectious diseases. Such initiatives present robust growth prospects for diagnostic kit suppliers.

Challenges and Market Constraints:

The presence of numerous market competitors exerts pressure on businesses to lower their prices, affecting the earnings of major international corporations. In addition, the low awareness of rapid diagnostic tests in African nations poses challenges to market penetration. Many developing and underdeveloped countries rely on government funding for rapid diagnostic test kits during epidemics, hindering direct market expansion.

Country-wise Insights:

United States Market Boom:

The United States has witnessed a surge in demand for infectious diagnostic tests, particularly in the wake of the COVID-19 pandemic. The increased incidence of chronic diseases has amplified the need for effective rapid medical diagnostic kits, with several companies actively developing and seeking FDA approval for these tests.

Lucrative Opportunities in Japan:

Japan, with its strong economy and high living standards, has seen a rise in infectious diseases' incidence. The country's free healthcare services and the authorization of diagnostic kits like Quick Navi - Flu2 have contributed to the expanding infectious diseases diagnostics market.

China's Emergence:

China is a prominent player in rapid medical diagnostics, with a multitude of manufacturers producing diagnostic kits that can accurately diagnose various ailments. Advances in multiplexing and profile test kits have accelerated market growth in China.

Canada's Growing Demand:

Canada is experiencing an increasing demand for early diagnosis due to the rising complexity of diseases and the need for timely detection. The Public Health Agency of Canada has reported an increase in the use of advanced kits for diagnosing diseases from biological samples, further boosting the infectious diseases diagnostics market.

Competitive Landscape:

Manufacturers are striving to develop high-quality diagnostic test kits at competitive prices to expand their market share. Additionally, companies are launching awareness campaigns to educate the public about infectious diseases, thereby increasing demand for their diagnostic test kits.

Key Companies Leading the Way:
• The competitive landscape of the Infectious Diseases Diagnostics Market includes key players such as Affymetrix, Inc.
• Ambion, Inc.
• Applera Corporation
• Cenetron Diagnostics
• Cepheid, Inc.
• Chiron Corporation
• Dharmacon, Inc.
• Digene Corporation
• Gen-Probe Incorporated
• Innogenetics NV
• Nanogen, Inc.
• F. Hoffmann-La Roche Ltd
• Becton, Dickinson and Company
• bioMérieux SA
• Hologic, Inc.,
• QIAGEN
• Myriad Genetics, Inc.,
• Thermo Fisher Scientific
• Meridian Bioscience, Inc

Key Segments Covered in Infectious Diseases Diagnostics Industry Research

Product:
• Instrument
Biochips
Microfluidics Based POCT
DNA Microarrays
Mass Spectrometry
Real-time Polymerase Chain Reaction (qPCR)
Fluorescence in situ Hybridization (FISH)
Sequencing

 Capillary Electrophoresis

 Next Generation Sequencing
• Kits and reagents
Kits
Primary antibodies
Secondary antibodies
Substrates
Buffers
• consumables

Test Type:
• Screening Test
• Diagnostic Test

Application:
• Hospital- Acquired Infections
• Sexually Transmitted Disease (STD)
• Sepsis
• Meningitis
• Respiratory Infections
• HPV
• Gastrointestinal Tract Infections
• Infection in Transplant Patients
• Hepatitis B and C
• Tuberculosis
• Others

End User:
• Hospitals
• Diagnostic Laboratories
• Clinics
• Academic and Research Institutes
• Others

Region:
• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa



The global Infectious Diseases Diagnostics Market is experiencing remarkable growth, with revenues reaching US$ 37 billion in 2024. Projections indicate that the market is on a trajectory to achieve a valuation of US$ 54 billion by the end of 2031, driven by several key factors shaping the industry.

Rising Incidence of Infectious Diseases and Focus on Evidence-based Medicine:

The prevalence of infectious diseases, including respiratory ailments and sexually transmitted infections, is surging worldwide. This has led to an imperative need for the diagnosis of these infectious diseases, driving growth in the infectious diseases diagnostics market.

Evidence-based medicine (EBM) is playing a pivotal role in healthcare, enhancing the quality of care, patient satisfaction, and cost-efficiency. EBM emphasizes evidence-driven diagnosis, resulting in a surge in demand for diagnostic kits. Rapid test kits are becoming increasingly essential as the global population grapples with infectious diseases, further boosting market growth.

Reliable Test Kits with Low-Cost Solutions:

Efficient diagnostic test kits for infectious diseases are currently in limited supply. The high cost of existing test kits and a lack of accessible diagnostic tools have prompted companies to focus on creating affordable and reliable solutions. Extensive research and development efforts are underway to produce highly accurate and sensitive diagnostic kits, creating new opportunities for market players.

Government Initiatives Driving Growth:

Various countries are proactively investing in infectious disease prevention to reduce healthcare costs. For instance, the India Health Fund, in collaboration with the Office of the Principal Scientific Adviser to the Government of India, is soliciting innovations to address urgent issues related to the control, treatment, and cure of infectious diseases. Such initiatives present robust growth prospects for diagnostic kit suppliers.

Challenges and Market Constraints:

The presence of numerous market competitors exerts pressure on businesses to lower their prices, affecting the earnings of major international corporations. In addition, the low awareness of rapid diagnostic tests in African nations poses challenges to market penetration. Many developing and underdeveloped countries rely on government funding for rapid diagnostic test kits during epidemics, hindering direct market expansion.

Country-wise Insights:

United States Market Boom:

The United States has witnessed a surge in demand for infectious diagnostic tests, particularly in the wake of the COVID-19 pandemic. The increased incidence of chronic diseases has amplified the need for effective rapid medical diagnostic kits, with several companies actively developing and seeking FDA approval for these tests.

Lucrative Opportunities in Japan:

Japan, with its strong economy and high living standards, has seen a rise in infectious diseases' incidence. The country's free healthcare services and the authorization of diagnostic kits like Quick Navi - Flu2 have contributed to the expanding infectious diseases diagnostics market.

China's Emergence:

China is a prominent player in rapid medical diagnostics, with a multitude of manufacturers producing diagnostic kits that can accurately diagnose various ailments. Advances in multiplexing and profile test kits have accelerated market growth in China.

Canada's Growing Demand:

Canada is experiencing an increasing demand for early diagnosis due to the rising complexity of diseases and the need for timely detection. The Public Health Agency of Canada has reported an increase in the use of advanced kits for diagnosing diseases from biological samples, further boosting the infectious diseases diagnostics market.

Competitive Landscape:

Manufacturers are striving to develop high-quality diagnostic test kits at competitive prices to expand their market share. Additionally, companies are launching awareness campaigns to educate the public about infectious diseases, thereby increasing demand for their diagnostic test kits.

Key Companies Leading the Way:
• The competitive landscape of the Infectious Diseases Diagnostics Market includes key players such as Affymetrix, Inc.
• Ambion, Inc.
• Applera Corporation
• Cenetron Diagnostics
• Cepheid, Inc.
• Chiron Corporation
• Dharmacon, Inc.
• Digene Corporation
• Gen-Probe Incorporated
• Innogenetics NV
• Nanogen, Inc.
• F. Hoffmann-La Roche Ltd
• Becton, Dickinson and Company
• bioMérieux SA
• Hologic, Inc.,
• QIAGEN
• Myriad Genetics, Inc.,
• Thermo Fisher Scientific
• Meridian Bioscience, Inc

Key Segments Covered in Infectious Diseases Diagnostics Industry Research

Product:
• Instrument
Biochips
Microfluidics Based POCT
DNA Microarrays
Mass Spectrometry
Real-time Polymerase Chain Reaction (qPCR)
Fluorescence in situ Hybridization (FISH)
Sequencing

 Capillary Electrophoresis

 Next Generation Sequencing
• Kits and reagents
Kits
Primary antibodies
Secondary antibodies
Substrates
Buffers
• consumables

Test Type:
• Screening Test
• Diagnostic Test

Application:
• Hospital- Acquired Infections
• Sexually Transmitted Disease (STD)
• Sepsis
• Meningitis
• Respiratory Infections
• HPV
• Gastrointestinal Tract Infections
• Infection in Transplant Patients
• Hepatitis B and C
• Tuberculosis
• Others

End User:
• Hospitals
• Diagnostic Laboratories
• Clinics
• Academic and Research Institutes
• Others

Region:
• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.


1. Executive Summary
1.1. Global Infectious Diseases Diagnostics Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Infectious Diseases Diagnostics Market Outlook, 2018 – 2031
3.1. Global Infectious Diseases Diagnostics Market Outlook, by Product, Value (US$ Bn), 2018 – 2031
3.1.1. Key Highlights
3.1.1.1. Instrument
3.1.1.1.1. Biochips
3.1.1.1.2. Microfluidics Based POCT
3.1.1.1.3. DNA Microarrays
3.1.1.1.4. Mass Spectrometry
3.1.1.1.5. Real-time Polymerase Chain Reaction (qPCR)
3.1.1.1.6. Fluorescence in situ Hybridization (FISH)
3.1.1.1.7. Sequencing
3.1.1.2. Kits and reagents
3.1.1.2.1. Kits
3.1.1.2.2. Primary antibodies
3.1.1.2.3. Secondary antibodies
3.1.1.2.4. Substrates
3.1.1.2.5. Buffers
3.1.1.3. Consumables
3.2. Global Infectious Diseases Diagnostics Market Outlook, by Test Type, Value (US$ Bn), 2018 – 2031
3.2.1. Key Highlights
3.2.1.1. Screening Test
3.2.1.2. Diagnostic Test
3.3. Global Infectious Diseases Diagnostics Market Outlook, by Application, Value (US$ Bn), 2018 – 2031
3.3.1. Key Highlights
3.3.1.1. Hospital- Acquired Infections
3.3.1.2. Sexually Transmitted Disease (STD)
3.3.1.3. Sepsis
3.3.1.4. Meningitis
3.3.1.5. Respiratory Infections
3.3.1.6. HPV
3.3.1.7. Gastrointestinal Tract Infections
3.3.1.8. Infection in Transplant Patients
3.3.1.9. Hepatitis B and C
3.3.1.10. Tuberculosis
3.3.1.11. Others
3.4. Global Infectious Diseases Diagnostics Market Outlook, by End User, Value (US$ Bn), 2018 – 2031
3.4.1. Key Highlights
3.4.1.1. Hospitals
3.4.1.2. Diagnostic Laboratories
3.4.1.3. Clinics
3.4.1.4. Academic and Research Institutes
3.4.1.5. Others
3.5. Global Infectious Diseases Diagnostics Market Outlook, by Region, Value (US$ Bn), 2018 – 2031
3.5.1. Key Highlights
3.5.1.1. North America
3.5.1.2. Europe
3.5.1.3. Asia Pacific
3.5.1.4. Latin America
3.5.1.5. Middle East & Africa
4. North America Infectious Diseases Diagnostics Market Outlook, 2018 – 2031
4.1. North America Infectious Diseases Diagnostics Market Outlook, by Product, Value (US$ Bn), 2018 – 2031
4.1.1. Key Highlights
4.1.1.1. Instrument
4.1.1.1.1. Biochips
4.1.1.1.2. Microfluidics Based POCT
4.1.1.1.3. DNA Microarrays
4.1.1.1.4. Mass Spectrometry
4.1.1.1.5. Real-time Polymerase Chain Reaction (qPCR)
4.1.1.1.6. Fluorescence in situ Hybridization (FISH)
4.1.1.1.7. Sequencing
4.1.1.2. Kits and reagents
4.1.1.2.1. Kits
4.1.1.2.2. Primary antibodies
4.1.1.2.3. Secondary antibodies
4.1.1.2.4. Substrates
4.1.1.2.5. Buffers
4.1.1.3. Consumables
4.2. North America Infectious Diseases Diagnostics Market Outlook, by Test Type, Value (US$ Bn), 2018 – 2031
4.2.1. Key Highlights
4.2.1.1. Screening Test
4.2.1.2. Diagnostic Test
4.3. North America Infectious Diseases Diagnostics Market Outlook, by Application, Value (US$ Bn), 2018 – 2031
4.3.1. Key Highlights
4.3.1.1. Hospital- Acquired Infections
4.3.1.2. Sexually Transmitted Disease (STD)
4.3.1.3. Sepsis
4.3.1.4. Meningitis
4.3.1.5. Respiratory Infections
4.3.1.6. HPV
4.3.1.7. Gastrointestinal Tract Infections
4.3.1.8. Infection in Transplant Patients
4.3.1.9. Hepatitis B and C
4.3.1.10. Tuberculosis
4.3.1.11. Others
4.4. North America Infectious Diseases Diagnostics Market Outlook, by End User, Value (US$ Bn), 2018 – 2031
4.4.1. Key Highlights
4.4.1.1. Hospitals
4.4.1.2. Diagnostic Laboratories
4.4.1.3. Clinics
4.4.1.4. Academic and Research Institutes
4.4.1.5. Others
4.5. North America Infectious Diseases Diagnostics Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
4.5.1. Key Highlights
4.5.1.1. U.S. Infectious Diseases Diagnostics Market by Product, Value (US$ Bn), 2018 – 2031
4.5.1.2. U.S. Infectious Diseases Diagnostics Market by Test Type, Value (US$ Bn), 2018 – 2031
4.5.1.3. U.S. Infectious Diseases Diagnostics Market by Application, Value (US$ Bn), 2018 – 2031
4.5.1.4. U.S. Infectious Diseases Diagnostics Market by End User, Value (US$ Bn), 2018 – 2031
4.5.1.5. Canada Infectious Diseases Diagnostics Market by Product, Value (US$ Bn), 2018 – 2031
4.5.1.6. Canada Infectious Diseases Diagnostics Market by Test Type, Value (US$ Bn), 2018 – 2031
4.5.1.7. Canada Infectious Diseases Diagnostics Market by Application, Value (US$ Bn), 2018 – 2031
4.5.1.8. Canada Infectious Diseases Diagnostics Market by End User, Value (US$ Bn), 2018 – 2031
4.5.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Infectious Diseases Diagnostics Market Outlook, 2018 – 2031
5.1. Europe Infectious Diseases Diagnostics Market Outlook, by Product, Value (US$ Bn), 2018 – 2031
5.1.1. Key Highlights
5.1.1.1. Instrument
5.1.1.1.1. Biochips
5.1.1.1.2. Microfluidics Based POCT
5.1.1.1.3. DNA Microarrays
5.1.1.1.4. Mass Spectrometry
5.1.1.1.5. Real-time Polymerase Chain Reaction (qPCR)
5.1.1.1.6. Fluorescence in situ Hybridization (FISH)
5.1.1.1.7. Sequencing
5.1.1.2. Kits and reagents
5.1.1.2.1. Kits
5.1.1.2.2. Primary antibodies
5.1.1.2.3. Secondary antibodies
5.1.1.2.4. Substrates
5.1.1.2.5. Buffers
5.1.1.3. Consumables
5.2. Europe Infectious Diseases Diagnostics Market Outlook, by Test Type, Value (US$ Bn), 2018 – 2031
5.2.1. Key Highlights
5.2.1.1. Screening Test
5.2.1.2. Diagnostic Test
5.3. Europe Infectious Diseases Diagnostics Market Outlook, by Application, Value (US$ Bn), 2018 – 2031
5.3.1. Key Highlights
5.3.1.1. Hospital- Acquired Infections
5.3.1.2. Sexually Transmitted Disease (STD)
5.3.1.3. Sepsis
5.3.1.4. Meningitis
5.3.1.5. Respiratory Infections
5.3.1.6. HPV
5.3.1.7. Gastrointestinal Tract Infections
5.3.1.8. Infection in Transplant Patients
5.3.1.9. Hepatitis B and C
5.3.1.10. Tuberculosis
5.3.1.11. Others
5.4. Europe Infectious Diseases Diagnostics Market Outlook, by End User, Value (US$ Bn), 2018 – 2031
5.4.1. Key Highlights
5.4.1.1. Hospitals
5.4.1.2. Diagnostic Laboratories
5.4.1.3. Clinics
5.4.1.4. Academic and Research Institutes
5.4.1.5. Others
5.5. Europe Infectious Diseases Diagnostics Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
5.5.1. Key Highlights
5.5.1.1. Germany Infectious Diseases Diagnostics Market by Product, Value (US$ Bn), 2018 – 2031
5.5.1.2. Germany Infectious Diseases Diagnostics Market by Test Type, Value (US$ Bn), 2018 – 2031
5.5.1.3. Germany Infectious Diseases Diagnostics Market by Application, Value (US$ Bn), 2018 – 2031
5.5.1.4. Germany Infectious Diseases Diagnostics Market by End User, Value (US$ Bn), 2018 – 2031
5.5.1.5. U.K. Infectious Diseases Diagnostics Market by Product, Value (US$ Bn), 2018 – 2031
5.5.1.6. U.K. Infectious Diseases Diagnostics Market by Test Type, Value (US$ Bn), 2018 – 2031
5.5.1.7. U.K. Infectious Diseases Diagnostics Market by Application, Value (US$ Bn), 2018 – 2031
5.5.1.8. U.K. Infectious Diseases Diagnostics Market by End User, Value (US$ Bn), 2018 – 2031
5.5.1.9. France Infectious Diseases Diagnostics Market by Product, Value (US$ Bn), 2018 – 2031
5.5.1.10. France Infectious Diseases Diagnostics Market by Test Type, Value (US$ Bn), 2018 – 2031
5.5.1.11. France Infectious Diseases Diagnostics Market by Application, Value (US$ Bn), 2018 – 2031
5.5.1.12. France Infectious Diseases Diagnostics Market by End User, Value (US$ Bn), 2018 – 2031
5.5.1.13. Italy Infectious Diseases Diagnostics Market by Product, Value (US$ Bn), 2018 – 2031
5.5.1.14. Italy Infectious Diseases Diagnostics Market by Test Type, Value (US$ Bn), 2018 – 2031
5.5.1.15. Italy Infectious Diseases Diagnostics Market by Application, Value (US$ Bn), 2018 – 2031
5.5.1.16. Italy Infectious Diseases Diagnostics Market by End User, Value (US$ Bn), 2018 – 2031
5.5.1.17. Turkey Infectious Diseases Diagnostics Market by Product, Value (US$ Bn), 2018 – 2031
5.5.1.18. Turkey Infectious Diseases Diagnostics Market by Test Type, Value (US$ Bn), 2018 – 2031
5.5.1.19. Turkey Infectious Diseases Diagnostics Market by Application, Value (US$ Bn), 2018 – 2031
5.5.1.20. Turkey Infectious Diseases Diagnostics Market by End User, Value (US$ Bn), 2018 – 2031
5.5.1.21. Russia Infectious Diseases Diagnostics Market by Product, Value (US$ Bn), 2018 – 2031
5.5.1.22. Russia Infectious Diseases Diagnostics Market by Test Type, Value (US$ Bn), 2018 – 2031
5.5.1.23. Russia Infectious Diseases Diagnostics Market by Application, Value (US$ Bn), 2018 – 2031
5.5.1.24. Russia Infectious Diseases Diagnostics Market by End User, Value (US$ Bn), 2018 – 2031
5.5.1.25. Rest of Europe Infectious Diseases Diagnostics Market by Product, Value (US$ Bn), 2018 – 2031
5.5.1.26. Rest of Europe Infectious Diseases Diagnostics Market by Test Type, Value (US$ Bn), 2018 – 2031
5.5.1.27. Rest of Europe Infectious Diseases Diagnostics Market by Application, Value (US$ Bn), 2018 – 2031
5.5.1.28. Rest of Europe Infectious Diseases Diagnostics Market by End User, Value (US$ Bn), 2018 – 2031
5.5.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Infectious Diseases Diagnostics Market Outlook, 2018 – 2031
6.1. Asia Pacific Infectious Diseases Diagnostics Market Outlook, by Product, Value (US$ Bn), 2018 – 2031
6.1.1. Key Highlights
6.1.1.1. Instrument
6.1.1.1.1. Biochips
6.1.1.1.2. Microfluidics Based POCT
6.1.1.1.3. DNA Microarrays
6.1.1.1.4. Mass Spectrometry
6.1.1.1.5. Real-time Polymerase Chain Reaction (qPCR)
6.1.1.1.6. Fluorescence in situ Hybridization (FISH)
6.1.1.1.7. Sequencing
6.1.1.2. Kits and reagents
6.1.1.2.1. Kits
6.1.1.2.2. Primary antibodies
6.1.1.2.3. Secondary antibodies
6.1.1.2.4. Substrates
6.1.1.2.5. Buffers
6.1.1.3. Consumables
6.2. Asia Pacific Infectious Diseases Diagnostics Market Outlook, by Test Type, Value (US$ Bn), 2018 – 2031
6.2.1. Key Highlights
6.2.1.1. Screening Test
6.2.1.2. Diagnostic Test
6.3. Asia Pacific Infectious Diseases Diagnostics Market Outlook, by Application, Value (US$ Bn), 2018 – 2031
6.3.1. Key Highlights
6.3.1.1. Hospital- Acquired Infections
6.3.1.2. Sexually Transmitted Disease (STD)
6.3.1.3. Sepsis
6.3.1.4. Meningitis
6.3.1.5. Respiratory Infections
6.3.1.6. HPV
6.3.1.7. Gastrointestinal Tract Infections
6.3.1.8. Infection in Transplant Patients
6.3.1.9. Hepatitis B and C
6.3.1.10. Tuberculosis
6.3.1.11. Others
6.4. Asia Pacific Infectious Diseases Diagnostics Market Outlook, by End User, Value (US$ Bn), 2018 – 2031
6.4.1. Key Highlights
6.4.1.1. Hospitals
6.4.1.2. Diagnostic Laboratories
6.4.1.3. Clinics
6.4.1.4. Academic and Research Institutes
6.4.1.5. Others
6.5. Asia Pacific Infectious Diseases Diagnostics Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
6.5.1. Key Highlights
6.5.1.1. China Infectious Diseases Diagnostics Market by Product, Value (US$ Bn), 2018 – 2031
6.5.1.2. China Infectious Diseases Diagnostics Market by Test Type, Value (US$ Bn), 2018 – 2031
6.5.1.3. China Infectious Diseases Diagnostics Market by Application, Value (US$ Bn), 2018 – 2031
6.5.1.4. China Infectious Diseases Diagnostics Market by End User, Value (US$ Bn), 2018 – 2031
6.5.1.5. Japan Infectious Diseases Diagnostics Market by Product, Value (US$ Bn), 2018 – 2031
6.5.1.6. Japan Infectious Diseases Diagnostics Market by Test Type, Value (US$ Bn), 2018 – 2031
6.5.1.7. Japan Infectious Diseases Diagnostics Market by Application, Value (US$ Bn), 2018 – 2031
6.5.1.8. Japan Infectious Diseases Diagnostics Market by End User, Value (US$ Bn), 2018 – 2031
6.5.1.9. South Korea Infectious Diseases Diagnostics Market by Product, Value (US$ Bn), 2018 – 2031
6.5.1.10. South Korea Infectious Diseases Diagnostics Market by Test Type, Value (US$ Bn), 2018 – 2031
6.5.1.11. South Korea Infectious Diseases Diagnostics Market by Application, Value (US$ Bn), 2018 – 2031
6.5.1.12. South Korea Infectious Diseases Diagnostics Market by End User, Value (US$ Bn), 2018 – 2031
6.5.1.13. India Infectious Diseases Diagnostics Market by Product, Value (US$ Bn), 2018 – 2031
6.5.1.14. India Infectious Diseases Diagnostics Market by Test Type, Value (US$ Bn), 2018 – 2031
6.5.1.15. India Infectious Diseases Diagnostics Market by Application, Value (US$ Bn), 2018 – 2031
6.5.1.16. India Infectious Diseases Diagnostics Market by End User, Value (US$ Bn), 2018 – 2031
6.5.1.17. Southeast Asia Infectious Diseases Diagnostics Market by Product, Value (US$ Bn), 2018 – 2031
6.5.1.18. Southeast Asia Infectious Diseases Diagnostics Market by Test Type, Value (US$ Bn), 2018 – 2031
6.5.1.19. Southeast Asia Infectious Diseases Diagnostics Market by Application, Value (US$ Bn), 2018 – 2031
6.5.1.20. Southeast Asia Infectious Diseases Diagnostics Market by End User, Value (US$ Bn), 2018 – 2031
6.5.1.21. Rest of Asia Pacific Infectious Diseases Diagnostics Market by Product, Value (US$ Bn), 2018 – 2031
6.5.1.22. Rest of Asia Pacific Infectious Diseases Diagnostics Market by Test Type, Value (US$ Bn), 2018 – 2031
6.5.1.23. Rest of Asia Pacific Infectious Diseases Diagnostics Market by Application, Value (US$ Bn), 2018 – 2031
6.5.1.24. Rest of Asia Pacific Infectious Diseases Diagnostics Market by End User, Value (US$ Bn), 2018 – 2031
6.5.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Infectious Diseases Diagnostics Market Outlook, 2018 – 2031
7.1. Latin America Infectious Diseases Diagnostics Market Outlook, by Product, Value (US$ Bn), 2018 – 2031
7.1.1. Key Highlights
7.1.1.1. Instrument
7.1.1.1.1. Biochips
7.1.1.1.2. Microfluidics Based POCT
7.1.1.1.3. DNA Microarrays
7.1.1.1.4. Mass Spectrometry
7.1.1.1.5. Real-time Polymerase Chain Reaction (qPCR)
7.1.1.1.6. Fluorescence in situ Hybridization (FISH)
7.1.1.1.7. Sequencing
7.1.1.2. Kits and reagents
7.1.1.2.1. Kits
7.1.1.2.2. Primary antibodies
7.1.1.2.3. Secondary antibodies
7.1.1.2.4. Substrates
7.1.1.2.5. Buffers
7.1.1.3. Consumables
7.2. Latin America Infectious Diseases Diagnostics Market Outlook, by Test Type, Value (US$ Bn), 2018 – 2031
7.2.1.1. Screening Test
7.2.1.2. Diagnostic Test
7.3. Latin America Infectious Diseases Diagnostics Market Outlook, by Application, Value (US$ Bn), 2018 – 2031
7.3.1. Key Highlights
7.3.1.1. Hospital- Acquired Infections
7.3.1.2. Sexually Transmitted Disease (STD)
7.3.1.3. Sepsis
7.3.1.4. Meningitis
7.3.1.5. Respiratory Infections
7.3.1.6. HPV
7.3.1.7. Gastrointestinal Tract Infections
7.3.1.8. Infection in Transplant Patients
7.3.1.9. Hepatitis B and C
7.3.1.10. Tuberculosis
7.3.1.11. Others
7.4. Latin America Infectious Diseases Diagnostics Market Outlook, by End User, Value (US$ Bn), 2018 – 2031
7.4.1. Key Highlights
7.4.1.1. Hospitals
7.4.1.2. Diagnostic Laboratories
7.4.1.3. Clinics
7.4.1.4. Academic and Research Institutes
7.4.1.5. Others
7.5. Latin America Infectious Diseases Diagnostics Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
7.5.1. Key Highlights
7.5.1.1. Brazil Infectious Diseases Diagnostics Market by Product, Value (US$ Bn), 2018 – 2031
7.5.1.2. Brazil Infectious Diseases Diagnostics Market by Test Type, Value (US$ Bn), 2018 – 2031
7.5.1.3. Brazil Infectious Diseases Diagnostics Market by Application, Value (US$ Bn), 2018 – 2031
7.5.1.4. Brazil Infectious Diseases Diagnostics Market by End User, Value (US$ Bn), 2018 – 2031
7.5.1.5. Mexico Infectious Diseases Diagnostics Market by Product, Value (US$ Bn), 2018 – 2031
7.5.1.6. Mexico Infectious Diseases Diagnostics Market by Test Type, Value (US$ Bn), 2018 – 2031
7.5.1.7. Mexico Infectious Diseases Diagnostics Market by Application, Value (US$ Bn), 2018 – 2031
7.5.1.8. Mexico Infectious Diseases Diagnostics Market by End User, Value (US$ Bn), 2018 – 2031
7.5.1.9. Argentina Infectious Diseases Diagnostics Market by Product, Value (US$ Bn), 2018 – 2031
7.5.1.10. Argentina Infectious Diseases Diagnostics Market by Test Type, Value (US$ Bn), 2018 – 2031
7.5.1.11. Argentina Infectious Diseases Diagnostics Market by Application, Value (US$ Bn), 2018 – 2031
7.5.1.12. Argentina Infectious Diseases Diagnostics Market by End User, Value (US$ Bn), 2018 – 2031
7.5.1.13. Rest of Latin America Infectious Diseases Diagnostics Market by Product, Value (US$ Bn), 2018 – 2031
7.5.1.14. Rest of Latin America Infectious Diseases Diagnostics Market by Test Type, Value (US$ Bn), 2018 – 2031
7.5.1.15. Rest of Latin America Infectious Diseases Diagnostics Market by Application, Value (US$ Bn), 2018 – 2031
7.5.1.16. Rest of Latin America Infectious Diseases Diagnostics Market by End User, Value (US$ Bn), 2018 – 2031
7.5.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Infectious Diseases Diagnostics Market Outlook, 2018 – 2031
8.1. Middle East & Africa Infectious Diseases Diagnostics Market Outlook, by Product, Value (US$ Bn), 2018 – 2031
8.1.1. Key Highlights
8.1.1.1. Instrument
8.1.1.1.1. Biochips
8.1.1.1.2. Microfluidics Based POCT
8.1.1.1.3. DNA Microarrays
8.1.1.1.4. Mass Spectrometry
8.1.1.1.5. Real-time Polymerase Chain Reaction (qPCR)
8.1.1.1.6. Fluorescence in situ Hybridization (FISH)
8.1.1.1.7. Sequencing
8.1.1.2. Kits and reagents
8.1.1.2.1. Kits
8.1.1.2.2. Primary antibodies
8.1.1.2.3. Secondary antibodies
8.1.1.2.4. Substrates
8.1.1.2.5. Buffers
8.1.1.3. Consumables
8.2. Middle East & Africa Infectious Diseases Diagnostics Market Outlook, by Test Type, Value (US$ Bn), 2018 – 2031
8.2.1. Key Highlights
8.2.1.1. Screening Test
8.2.1.2. Diagnostic Test
8.3. Middle East & Africa Infectious Diseases Diagnostics Market Outlook, by Application, Value (US$ Bn), 2018 – 2031
8.3.1. Key Highlights
8.3.1.1. Hospital- Acquired Infections
8.3.1.2. Sexually Transmitted Disease (STD)
8.3.1.3. Sepsis
8.3.1.4. Meningitis
8.3.1.5. Respiratory Infections
8.3.1.6. HPV
8.3.1.7. Gastrointestinal Tract Infections
8.3.1.8. Infection in Transplant Patients
8.3.1.9. Hepatitis B and C
8.3.1.10. Tuberculosis
8.3.1.11. Others
8.4. Middle East & Africa Infectious Diseases Diagnostics Market Outlook, by End User, Value (US$ Bn), 2018 – 2031
8.4.1. Key Highlights
8.4.1.1. Hospitals
8.4.1.2. Diagnostic Laboratories
8.4.1.3. Clinics
8.4.1.4. Academic and Research Institutes
8.4.1.5. Others
8.5. Middle East & Africa Infectious Diseases Diagnostics Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
8.5.1. Key Highlights
8.5.1.1. GCC Infectious Diseases Diagnostics Market by Product, Value (US$ Bn), 2018 – 2031
8.5.1.2. GCC Infectious Diseases Diagnostics Market by Test Type, Value (US$ Bn), 2018 – 2031
8.5.1.3. GCC Infectious Diseases Diagnostics Market by Application, Value (US$ Bn), 2018 – 2031
8.5.1.4. GCC Infectious Diseases Diagnostics Market by End User, Value (US$ Bn), 2018 – 2031
8.5.1.5. South Africa Infectious Diseases Diagnostics Market by Product, Value (US$ Bn), 2018 – 2031
8.5.1.6. South Africa Infectious Diseases Diagnostics Market by Test Type, Value (US$ Bn), 2018 – 2031
8.5.1.7. South Africa Infectious Diseases Diagnostics Market by Application, Value (US$ Bn), 2018 – 2031
8.5.1.8. South Africa Infectious Diseases Diagnostics Market by End User, Value (US$ Bn), 2018 – 2031
8.5.1.9. Egypt Infectious Diseases Diagnostics Market by Product, Value (US$ Bn), 2018 – 2031
8.5.1.10. Egypt Infectious Diseases Diagnostics Market by Test Type, Value (US$ Bn), 2018 – 2031
8.5.1.11. Egypt Infectious Diseases Diagnostics Market by Application, Value (US$ Bn), 2018 – 2031
8.5.1.12. Egypt Infectious Diseases Diagnostics Market by End User, Value (US$ Bn), 2018 – 2031
8.5.1.13. Nigeria Infectious Diseases Diagnostics Market by Product, Value (US$ Bn), 2018 – 2031
8.5.1.14. Nigeria Infectious Diseases Diagnostics Market by Test Type, Value (US$ Bn), 2018 – 2031
8.5.1.15. Nigeria Infectious Diseases Diagnostics Market by Application, Value (US$ Bn), 2018 – 2031
8.5.1.16. Nigeria Infectious Diseases Diagnostics Market by End User, Value (US$ Bn), 2018 – 2031
8.5.1.17. Rest of Middle East & Africa Infectious Diseases Diagnostics Market by Product, Value (US$ Bn), 2018 – 2031
8.5.1.18. Rest of Middle East & Africa Infectious Diseases Diagnostics Market by Test Type, Value (US$ Bn), 2018 – 2031
8.5.1.19. Rest of Middle East & Africa Infectious Diseases Diagnostics Market by Application, Value (US$ Bn), 2018 – 2031
8.5.1.20. Rest of Middle East & Africa Infectious Diseases Diagnostics Market by End User, Value (US$ Bn), 2018 – 2031
8.5.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. By Application vs By Test Type Heatmap
9.2. Manufacturer vs By Test Type Heatmap
9.3. Company Market Share Analysis, 2023
9.4. Competitive Dashboard
9.5. Company Profiles
9.5.1. Affymetrix, Inc.
9.5.1.1. Company Overview
9.5.1.2. Product Portfolio
9.5.1.3. Financial Overview
9.5.1.4. Business Strategies and Development
9.5.2. Ambion, Inc.
9.5.2.1. Company Overview
9.5.2.2. Product Portfolio
9.5.2.3. Financial Overview
9.5.2.4. Business Strategies and Development
9.5.3. Applera Corporation
9.5.3.1. Company Overview
9.5.3.2. Product Portfolio
9.5.3.3. Financial Overview
9.5.3.4. Business Strategies and Development
9.5.4. Cenetron Diagnostics
9.5.4.1. Company Overview
9.5.4.2. Product Portfolio
9.5.4.3. Financial Overview
9.5.4.4. Business Strategies and Development
9.5.5. Cepheid, Inc.
9.5.5.1. Company Overview
9.5.5.2. Product Portfolio
9.5.5.3. Financial Overview
9.5.5.4. Business Strategies and Development
9.5.6. Chiron Corporation
9.5.6.1. Company Overview
9.5.6.2. Product Portfolio
9.5.6.3. Financial Overview
9.5.6.4. Business Strategies and Development
9.5.7. Dharmacon, Inc.
9.5.7.1. Company Overview
9.5.7.2. Product Portfolio
9.5.7.3. Financial Overview
9.5.7.4. Business Strategies and Development
9.5.8. Digene Corporation
9.5.8.1. Company Overview
9.5.8.2. Product Portfolio
9.5.8.3. Financial Overview
9.5.8.4. Business Strategies and Development
9.5.9. Gen-Probe Incorporated
9.5.9.1. Company Overview
9.5.9.2. Product Portfolio
9.5.9.3. Financial Overview
9.5.9.4. Business Strategies and Development
9.5.10. Innogenetics NV
9.5.10.1. Company Overview
9.5.10.2. Product Portfolio
9.5.10.3. Financial Overview
9.5.10.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings